News

Heart failure exacerbation by saxagliptin called ‘real’

Publish date: December 3, 2013

 

AT THE AHA SCIENTIFIC SESSIONS

mzoler@frontlinemedcom.com

On Twitter @mitchelzoler

Pages

Recommended Reading

Combined angiotensin inhibition raises hyperkalemia, acute kidney injury risks
MDedge Endocrinology
ACC-AHA cardiovascular prevention guidelines drop cholesterol treatment goals
MDedge Endocrinology
CORAL: No added benefit with renal stenting vs. medication alone
MDedge Endocrinology
Abandon LDL targets? Not yet
MDedge Endocrinology
Guideline authors, AHA-ACC leaders confident in risk calculator
MDedge Endocrinology
VIDEO: AHA/ACC work group cochair defends, explains risk calculator
MDedge Endocrinology
AHA/ACC prevention guidelines: Clinician perspective
MDedge Endocrinology
FDA lifts rosiglitazone prescribing restrictions
MDedge Endocrinology
Chelation plus vitamins halved cardiovascular events in diabetics
MDedge Endocrinology
Analysis: No such thing as ‘benign’ obesity
MDedge Endocrinology

Related Articles